Literature DB >> 31145701

Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.

Shigeki Sekine1,2, Tohru Kiyono3,4, Eijitsu Ryo2, Reiko Ogawa2, Susumu Wakai1, Hitoshi Ichikawa5, Koyu Suzuki6, Satoru Arai7, Koji Tsuta8, Mitsuaki Ishida8, Yuko Sasajima9, Naoki Goshima10, Naoya Yamazaki11, Taisuke Mori1,2.   

Abstract

Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in the tumorigenesis of poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 lesions, 88.5%) and their rare malignant counterpart, porocarcinomas (7/11 lesions, 63.6%). A WWTR1-NUTM1 fusion was identified in a single lesion of poroma. Fluorescent in-situ hybridization confirmed genomic rearrangements involving these genetic loci. Immunohistochemical staining could readily identify the YAP1 fusion products as nuclear expression of the N-terminal portion of YAP1 with a lack of the C-terminal portion. YAP1 and WWTR1, also known as YAP and TAZ, respectively, encode paralogous transcriptional activators of TEAD, which are negatively regulated by the Hippo signaling pathway. The YAP1 and WWTR1 fusions strongly transactivated a TEAD reporter and promoted anchorage-independent growth, confirming their tumorigenic roles. Our results demonstrate the frequent presence of transforming YAP1 fusions in poromas and porocarcinomas and suggest YAP1/TEAD-dependent transcription as a candidate therapeutic target against porocarcinoma.

Entities:  

Keywords:  Dermatology; Oncogenes; Oncology; Skin cancer

Mesh:

Substances:

Year:  2019        PMID: 31145701      PMCID: PMC6715383          DOI: 10.1172/JCI126185

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit.

Authors:  P GOLDMAN; H PINKUS; J R ROGIN
Journal:  AMA Arch Derm       Date:  1956-11

2.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.

Authors:  Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

3.  Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation.

Authors:  Lizi Wu; Jingxuan Liu; Ping Gao; Makoto Nakamura; Yang Cao; Huangxuan Shen; James D Griffin
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

4.  From hidroacanthoma simplex to poroid hidradenoma: clinicopathologic and immunohistochemic study of poroid neoplasms and reappraisal of their histogenesis.

Authors:  Maxime Battistella; Lutz Langbein; Bernard Peltre; Bernard Cribier
Journal:  Am J Dermatopathol       Date:  2010-07       Impact factor: 1.533

5.  Histopathological and immunohistochemical studies of poroid hidradenoma.

Authors:  Han-Nan Liu; Yun-Ting Chang; Chih-Chiang Chen; Cheng-Hung Huang
Journal:  Arch Dermatol Res       Date:  2005-11-10       Impact factor: 3.017

Review 6.  Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases.

Authors:  A Robson; J Greene; N Ansari; B Kim; P T Seed; P H McKee; E Calonje
Journal:  Am J Surg Pathol       Date:  2001-06       Impact factor: 6.394

7.  A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.

Authors:  Costantino Errani; Lei Zhang; Yun Shao Sung; Mihai Hajdu; Samuel Singer; Robert G Maki; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2011-05-16       Impact factor: 5.006

8.  t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway.

Authors:  Giovanni Tonon; Sanjay Modi; Lizi Wu; Akihito Kubo; Amy B Coxon; Takefumi Komiya; Kevin O'Neil; Kristen Stover; Adel El-Naggar; James D Griffin; Ilan R Kirsch; Frederic J Kaye
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

9.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors:  Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

10.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

View more
  38 in total

1.  TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.

Authors:  Nicole Merritt; Keith Garcia; Dushyandi Rajendran; Zhen-Yuan Lin; Xiaomeng Zhang; Katrina A Mitchell; Nicholas Borcherding; Colleen Fullenkamp; Michael S Chimenti; Anne-Claude Gingras; Kieran F Harvey; Munir R Tanas
Journal:  Elife       Date:  2021-04-29       Impact factor: 8.140

2.  Recurrent PTBP1::MAML2 fusions in composite hemangioendothelioma with neuroendocrine differentiation: A report of two cases involving neck lymph nodes.

Authors:  Josephine K Dermawan; William H Westra; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2021-12-11       Impact factor: 5.006

3.  A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Ben Davidson; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

4.  Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-A genetic subset associated with cardiac involvement.

Authors:  Albert J H Suurmeijer; Brendan C Dickson; David Swanson; Yun S Sung; Lei Zhang; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2020-03-20       Impact factor: 5.006

5.  MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.

Authors:  Jiyoung Kim; Hyeryun Kwon; You Keun Shin; Gahyeon Song; Taebok Lee; Youngeun Kim; Wonyoung Jeong; Ukjin Lee; Xianglan Zhang; Gilyeong Nam; Hei-Cheul Jeung; Wantae Kim; Eek-Hoon Jho
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-01       Impact factor: 11.205

Review 6.  Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas.

Authors:  Pranjali P Kanvinde; Adarsha P Malla; Nina P Connolly; Frank Szulzewsky; Pavlos Anastasiadis; Heather M Ames; Anthony J Kim; Jeffrey A Winkles; Eric C Holland; Graeme F Woodworth
Journal:  Glia       Date:  2021-02-27       Impact factor: 7.452

7.  Eccrine poroma presented as spindle-shaped plaque: A case report.

Authors:  Yuqian Wang; Meng Liu; Yan Zheng; Yiguo Feng
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 8.  Hippo-Independent Regulation of Yki/Yap/Taz: A Non-canonical View.

Authors:  Yong Suk Cho; Jin Jiang
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 9.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 10.  Mutations and Copy Number Abnormalities of Hippo Pathway Components in Human Cancers.

Authors:  Zhengjin He; Ruihan Li; Hai Jiang
Journal:  Front Cell Dev Biol       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.